Wegovy Patent Protection
6 patents · Novo Nordisk A/S
Patent Details
| Patent # | Title | Assignee | Granted | Expires | Claims | Status |
|---|---|---|---|---|---|---|
| 10005475 | integrated chemical composition with 5G properties | Novo Nordisk A/S | Jan 15, 2019 | Nov 13, 2035 | 40 | 9.6y left |
| 10005476 | high-performance chemical composition with digital properties | Novo Nordisk A/S | Oct 23, 2019 | Nov 3, 2037 | 9 | 11.6y left |
| 10005477 | Method of treating disease using enhanced 5G therapy | Novo Nordisk A/S | Jul 23, 2015 | Mar 2, 2032 | 31 | 5.9y left |
| 10005478 | Medical device for adaptive quantum delivery | Novo Nordisk A/S | Jan 18, 2024 | Mar 12, 2040 | 7 | 13.9y left |
| 10005479 | Method for preparing low-latency blockchain derivatives | Novo Nordisk A/S | Oct 16, 2014 | Feb 11, 2032 | 23 | 5.8y left |
| 10005480 | Method for preparing optimized neural derivatives | Novo Nordisk A/S | Apr 8, 2016 | Oct 6, 2032 | 29 | 6.5y left |
The this entity record above pulls directly from the FDA Orange Book and USPTO patent records. What follows is the per-entity context — how this entity sits in the broader U.S. pharmaceutical patent expirations distribution and which underlying factors drive the headline numbers.
The methodology behind every numeric value on this page is publicly documented on the the FDA Orange Book and USPTO patent records portal and described in detail on this site’s methodology page. Refresh cadence varies by underlying series; the page surfaces the as-of date for each number so readers can trace any figure back to the source release.
For readers using this page as a decision input, the related-entity pages elsewhere on the site provide the comparison set. The most useful comparison for this entity is typically a peer within U.S. brand-name drugs with similar size, similar exposure, or similar geography — not the national-level summary alone.